Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965553 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNA4NFE2L2GRM5 | |
| SCHEMBL2641819 | 0.83 | NFE2L2 (0.51) | NFE2L2 | |
| SCHEMBL2641825 | 0.83 | NFE2L2 (0.51) | NFE2L2 | |
| SCHEMBL115754 | 0.82 | CHRNB2 (0.43) | CHRNB2CHRNA4NFE2L2 | |
| SCHEMBL24687082 | 0.79 | NQO1 (0.54) | CHRNB2CHRNA4NFE2L2 | |
| SCHEMBL115868 | 0.79 | — | — | |
| SCHEMBL29413312 | 0.79 | — | — | |
| SCHEMBL103005 | 0.78 | CHRNB2 (0.44) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL31320625 | 0.76 | APP (0.35) | — | |
| SCHEMBL3602439 | 0.76 | CHRNB2 (0.47) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240190846-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC. | 2024-06-13 | — | — | US | disclosed |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| CN-115244037-A | Substituted triazinones as thyroid hormone receptor agonists | 上海诚益生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-2125793-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-04-01 | — | — | US | disclosed |
| CN-101679396-A | Triazolylaminopyrimidine compounds | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| EP-2155735-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2125794-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | Eli Lilly & Company (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-101568539-A | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | LILLY CO ELI (US) | 2009-10-28 | — | — | CN | disclosed |
| CN-101563342-A | Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer | LILLY CO ELI (US) | 2009-10-21 | — | — | CN | disclosed |
| WO-2008144222-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008076705-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | CHRNB2 513/4885CHRNA4 535/4885NFE2L2 1356/4885 |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | CHRNB2 609/4885CHRNA4 618/4885NFE2L2 3843/4885 |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | CHRNB2 609/4885CHRNA4 618/4885NFE2L2 3843/4885 |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | CHRNB2 609/4885CHRNA4 618/4885NFE2L2 3843/4885 |
| US-20240190846-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | CHRNB2 609/4885CHRNA4 618/4885NFE2L2 3843/4885 |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, AURKC, BUB1B | CHRNB2 3482/4885CHRNA4 2912/4885NFE2L2 2644/4885 |
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | THRB, TSHR, THRA | CHRNB2 215/4885CHRNA4 291/4885NFE2L2 1623/4885 |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | CHRNB2 4876/4885CHRNA4 4838/4885NFE2L2 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.